An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With the Aliskiren 300 mg Plus Hydrochlorothiazide 25 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With Candesartan 32 mg Plus Hydrochlorothiazide 25 mg.

Trial Profile

An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With the Aliskiren 300 mg Plus Hydrochlorothiazide 25 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With Candesartan 32 mg Plus Hydrochlorothiazide 25 mg.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs Aliskiren/hydrochlorothiazide (Primary) ; Amlodipine; Candesartan cilexetil/hydrochlorothiazide
  • Indications Hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms AMAZING
  • Most Recent Events

    • 21 Jul 2012 Sandoz, Takeda Pharma added as associations as reported in the European Clinical Trials Database record.
    • 14 Apr 2012 New source identified and integrated (European Clinical Trials Database record EudraCT2008-005810-39).
    • 02 Jun 2010 Trial phase changed from III to IV as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top